

High-Sensitivity ST2 for Prediction of Adverse Outcome

Circulation: Heart Failure

4, 180-187

DOI: [10.1161/circheartfailure.110.958223](https://doi.org/10.1161/circheartfailure.110.958223)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Biomarkers in Advanced Heart Failure: Diagnostic and Therapeutic Insights. <i>Congestive Heart Failure</i> , 2011, 17, 169-174.	2.0	13
2	Establishing Prognosis in Heart Failure: A Multimarker Approach. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 86-96.	3.1	45
3	Use of Novel and Conventional Biomarkers for Management of Patients With Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 475-488.	0.9	7
4	Role of IL-33 in inflammation and disease. <i>Journal of Inflammation</i> , 2011, 8, 22.	3.4	368
5	Directions from Hecate: towards a multi-marker approach for heart failure assessment. <i>European Journal of Heart Failure</i> , 2011, 13, 691-693.	7.1	4
6	Circulation: Heart Failure's Editors' Picks: Most Important Papers in Epidemiology and Outcomes. <i>Circulation: Heart Failure</i> , 2011, 4, .	3.9	0
7	Soluble ST2 Is Regulated by p75 Neurotrophin Receptor and Predicts Mortality in Diabetic Patients With Critical Limb Ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, e149-60.	2.4	42
8	Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. <i>Clinical Chemistry</i> , 2012, 58, 1673-1681.	3.2	162
9	Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 32-38.	7.1	130
10	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66
11	Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. <i>Critical Care</i> , 2012, 16, R135.	5.8	33
12	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. <i>Circulation</i> , 2012, 126, 1596-1604.	1.6	414
13	Performance of the Seattle Heart Failure Model in Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2012, 110, 398-402.	1.6	21
14	Defining the Role of ST2: A Multimarker Approach?. <i>Journal of Cardiac Failure</i> , 2012, 18, 311-312.	1.7	1
15	Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit â€” The Linz Intensive Care Unit (LICU) study. <i>Clinica Chimica Acta</i> , 2012, 413, 587-593.	1.1	16
16	Prognostic Impact of the Addition of Ventilatory Efficiency to the Seattle Heart Failure Model in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2012, 18, 614-619.	1.7	14
17	Clinical Adoption of Prognostic Biomarkers: The Case for Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 3-13.	3.1	26
18	Transcriptomic Biomarkers of Cardiovascular Disease. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 64-69.	3.1	60

#	ARTICLE	IF	CITATIONS
19	Experimental biomarkers in heart failure: an update. Expert Review of Cardiovascular Therapy, 2012, 10, 1119-1132.	1.5	3
20	Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. Journal of Nuclear Cardiology, 2012, 19, 1007-1016.	2.1	60
21	Novel biomarkers in chronic heart failure. Nature Reviews Cardiology, 2012, 9, 347-359.	13.7	108
22	Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circulation: Heart Failure, 2012, 5, 183-190.	3.9	169
23	The Use of Biomarkers in the Patient with Heart Failure. Current Cardiology Reports, 2013, 15, 372.	2.9	34
24	Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. Journal of Cardiovascular Translational Research, 2013, 6, 485-492.	2.4	66
25	New and Emerging Biomarkers in Left Ventricular Systolic Dysfunctionâ€”Insight into Dilated Cardiomyopathy. Journal of Cardiovascular Translational Research, 2013, 6, 516-527.	2.4	29
26	Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. American Heart Journal, 2013, 165, 995-999.	2.7	110
27	The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. Current Heart Failure Reports, 2013, 10, 441-449.	3.3	27
28	Incorporating Common Biomarkers into the Clinical Management of Heart Failure. Current Heart Failure Reports, 2013, 10, 450-457.	3.3	5
29	Therapeutic Implications of Biomarkers in Chronic Heart Failure. Clinical Pharmacology and Therapeutics, 2013, 94, 468-479.	4.7	19
30	Heart Failure Biomarkers. Journal of Cardiovascular Translational Research, 2013, 6, 471-484.	2.4	17
31	Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients. Journal of Cardiac Failure, 2013, 19, 163-168.	1.7	74
32	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2013, 168, 1545-1547.	1.7	50
33	Temporal changes of soluble <sc>ST</sc>2 after cardiovascular interventions. European Journal of Clinical Investigation, 2013, 43, 113-120.	3.4	18
34	Biomarkers and diagnostics in heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2442-2450.	3.8	298
35	Heart Failure. JACC: Heart Failure, 2013, 1, 1-20.	4.1	612
36	ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. Journal of Cardiovascular Translational Research, 2013, 6, 493-500.	2.4	77

#	ARTICLE	IF	CITATIONS
37	Cardiac Markers. , 2013, , 817-831.		6
38	Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2013, 182, 82-98.	1.1	135
39	Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2013, 182, 99-116.	1.1	83
40	Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1165-1172.	2.8	189
41	The Presage [®] ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Review of Molecular Diagnostics, 2013, 13, 13-30.	3.1	79
42	Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome. Critical Care Medicine, 2013, 41, 2521-2531.	0.9	47
43	Soluble ST2 Is Associated with All-Cause and Cardiovascular Mortality in a Population-Based Cohort: The Dallas Heart Study. Clinical Chemistry, 2013, 59, 536-546.	3.2	58
44	Soluble ST2 in Ambulatory Patients With Heart Failure. Circulation: Heart Failure, 2013, 6, 1172-1179.	3.9	114
45	Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β -Blocker Therapy in Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 1206-1213.	3.9	116
46	Soluble ST2 predicts elevated SBP in the community. Journal of Hypertension, 2013, 31, 1431-1436.	0.5	42
47	Old and newer biomarkers in heart failure. Journal of Cardiovascular Medicine, 2013, 14, 690-697.	1.5	9
48	Soluble ST2 protein in chronic heart failure is independent of traditional factors. Archives of Medical Science, 2013, 1, 21-26.	0.9	25
49	A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats. PLoS ONE, 2013, 8, e79176.	2.5	37
50	A Novel Cardiac Bio-Marker: ST2: A Review. Molecules, 2013, 18, 15314-15328.	3.8	114
51	A structured home visit program by non-licensed healthcare personnel can make a difference in the management and readmission of heart failure patients. Journal of Hospital Administration, 2013, 3, 1.	0.1	2
52	The Prognostic Value of Plasma Soluble ST2 in Hospitalized Chinese Patients with Heart Failure. PLoS ONE, 2014, 9, e110976.	2.5	10
53	Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence. Current Cardiology Reviews, 2014, 11, 80-89.	1.5	18
54	Elevated Soluble ST2 and Depression Increased the Risk of All-Cause Mortality and Hospitalization in Patients With Heart Failure. International Heart Journal, 2014, 55, 445-450.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomarkers in Medicine, 2014, 8, 95-106.	1.4	15
56	The ease of use and reproducibility of the Alereâ„¢ Heart Check System: a comparison of patient and healthcare professional measurement of BNP. Biomarkers in Medicine, 2014, 8, 791-796.	1.4	14
57	Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study. Heart Rhythm, 2014, 11, 2167-2175.	0.7	46
58	ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart, 2014, 100, 1715-1721.	2.9	42
59	Plasma Soluble <sc>ST2</sc> Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension. Clinical Cardiology, 2014, 37, 365-370.	1.8	44
60	Using ST2 in cardiovascular patients: a review. Future Cardiology, 2014, 10, 525-539.	1.2	59
61	Increased Soluble ST2 Predicts Long-term Mortality in Patients with Stable Coronary Artery Disease: Results from the Ludwigshafen Risk and Cardiovascular Health Study. Clinical Chemistry, 2014, 60, 530-540.	3.2	102
62	Role of point of care - ST ₂ , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients. International Journal of Critical Illness and Injury Science, 2014, 4, 261.	0.6	2
63	STOP-HF: Expanding the role of HF programs into the community. Global Cardiology Science & Practice, 2014, 2014, 23.	0.4	0
64	Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Blood Purification, 2014, 37, 2-13.	1.8	7
65	Cardiac and Renal Fibrosis in Chronic Cardiorenal Syndromes. Nephron Clinical Practice, 2014, 127, 106-112.	2.3	35
66	Cardiorenal Syndrome. Heart Failure Clinics, 2014, 10, 251-280.	2.1	115
67	Soluble ST2 and Galectin-3 in Heart Failure. Clinics in Laboratory Medicine, 2014, 34, 87-97.	1.4	32
68	Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 65-72.	4.1	167
69	Heart Failure With Recovered Ejection Fraction. Circulation, 2014, 129, 2380-2387.	1.6	244
70	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. Journal of the American College of Cardiology, 2014, 63, 158-166.	2.8	222
71	Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure. Journal of the American Heart Association, 2014, 3, e000550.	3.7	81
72	Incremental Utility of Iodine-123 Meta-Iodobenzylguanidine Imaging Beyond Established Heart Failure Risk Models. Journal of Cardiac Failure, 2014, 20, 577-583.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Biomarkers in Pulmonary Arterial Hypertension. Current Heart Failure Reports, 2014, 11, 477-484.	3.3	13
74	Determinants and implications of elevated soluble ST2 levels in heart failure. International Journal of Cardiology, 2014, 176, 1242-1243.	1.7	9
75	Factors Influencing the Predictive Power of Models for Predicting Mortality and/or Heart Failure Hospitalization in Patients With Heart Failure. JACC: Heart Failure, 2014, 2, 429-436.	4.1	241
76	Biomarker Predictors of Cardiac Hospitalization in Chronic Heart Failure: A Recurrent Event Analysis. Journal of Cardiac Failure, 2014, 20, 569-576.	1.7	26
77	Heart Failure Risk Prediction Models. JACC: Heart Failure, 2014, 2, 437-439.	4.1	26
78	Transcriptomic biomarkers in safety and risk assessment of chemicals. , 2014, , 1033-1038.		9
79	Contemporary Strategies in the Diagnosis and Management of Heart Failure. Mayo Clinic Proceedings, 2014, 89, 662-676.	3.0	24
80	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 260-268.	4.1	104
81	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. European Journal of Clinical Investigation, 2015, 45, 899-905.	3.4	19
82	Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arquivos Brasileiros De Cardiologia, 2015, 106, 145-52.	0.8	73
83	Combined Biomarker Analysis for Risk of Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2015, 10, e0125282.	2.5	37
84	Elevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis. PLoS ONE, 2015, 10, e0138940.	2.5	47
85	Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders. Journal of Lipids, 2015, 2015, 1-50.	4.8	201
86	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides – The Case for Soluble ST2. European Cardiology Review, 2015, 10, 37.	2.2	8
87	Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7249-7254.	7.1	143
88	Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot?. Perfusion (United Kingdom), 2015, 30, 356-374.	1.0	5
89	Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. , 2015, , 105-116.		0
90	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	1.7	60

#	ARTICLE	IF	CITATIONS
91	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. Journal of Cardiac Failure, 2015, 21, 355-361.	1.7	31
92	ST2 and Patient Prognosis in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 64B-69B.	1.6	53
93	Structural Heart Disease and ST2: Cross-Sectional and Longitudinal Associations With Echocardiography. American Journal of Cardiology, 2015, 115, 59B-63B.	1.6	30
94	Multimarker Testing With ST2 in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 76B-80B.	1.6	19
95	Soluble ST2 in Ventricular Dysfunction. Advances in Clinical Chemistry, 2015, 69, 139-159.	3.7	8
96	Imaging the patient with a new diagnosis of heart failure in the contemporary era. Journal of Nuclear Cardiology, 2015, 22, 975-979.	2.1	0
97	Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. International Journal of Cardiology, 2015, 178, 284-291.	1.7	26
98	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart, 2015, 101, 1382-1388.	2.9	90
99	Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC: Heart Failure, 2015, 3, 591-599.	4.1	65
100	Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. International Journal of Cardiology, 2015, 186, 146-147.	1.7	5
101	State of the Art: Newer biomarkers in heart failure. European Journal of Heart Failure, 2015, 17, 559-569.	7.1	151
102	Soluble ST2â€™Analytical Considerations. American Journal of Cardiology, 2015, 115, 8B-21B.	1.6	86
103	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal, 2015, 170, 290-297.e1.	2.7	57
104	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. Current Heart Failure Reports, 2015, 12, 318-327.	3.3	10
105	Candidate biomarkers in heart failure with reduced and preserved ejection fraction. Biomarkers, 2015, 20, 258-265.	1.9	6
106	Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators. Clinica Chimica Acta, 2015, 443, 3-8.	1.1	30
107	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	1.1	70
108	Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. International Journal of Cardiology, 2015, 179, 378-384.	1.7	31

#	ARTICLE	IF	CITATIONS
109	Soluble ST2 in heart failure. Clinica Chimica Acta, 2015, 443, 57-70.	1.1	114
110	Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection. American Journal of Transplantation, 2016, 16, 938-950.	4.7	34
111	Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications. Archiv Der Pharmazie, 2016, 349, 399-409.	4.1	9
112	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.	7.1	54
113	Left Ventricular Contactile Reserve. , 2016, , 127-148.		2
114	The search for efficient diagnostic and prognostic biomarkers of heart failure. Future Cardiology, 2016, 12, 327-337.	1.2	1
115	Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure. Current Heart Failure Reports, 2016, 13, 207-218.	3.3	17
116	Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Communityâ€dwelling Population. Journal of the American Heart Association, 2016, 5, .	3.7	67
118	Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT. Journal of Cardiovascular Translational Research, 2016, 9, 421-428.	2.4	30
119	Biomarkers in Heart Failure: ST2. , 2016, , 251-268.		0
120	Prognostic Value of Baseline and ChangesÂin Circulating Soluble ST2 LevelsÂand the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77.	4.1	45
121	The soluble receptor ST2 is positively associated with occupational exposure to radiation. International Journal of Radiation Biology, 2016, 92, 87-93.	1.8	4
122	Development and evaluation of multi-marker risk scores for clinical prognosis. Statistical Methods in Medical Research, 2016, 25, 255-271.	1.5	18
123	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 256-262.	1.7	46
124	Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. American Journal of Medicine, 2016, 129, 560-567.	1.5	55
125	The fibrosis-cell death axis in heart failure. Heart Failure Reviews, 2016, 21, 199-211.	3.9	214
126	Novel Biomarkers of Heart Failure: Do They Have Incremental Clinical Utility?. Journal of Cardiac Failure, 2016, 22, 263-264.	1.7	0
127	Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. Biomarkers, 2017, 22, 367-371.	1.9	24

#	ARTICLE	IF	CITATIONS
128	Sparse Simultaneous Signal Detection for Identifying Genetically Controlled Disease Genes. Journal of the American Statistical Association, 2017, 112, 1032-1046.	3.1	9
129	Estratificação prognóstica na hipertensão pulmonar: valor acrescido da abordagem multibiomarcadores. Revista Portuguesa De Cardiologia, 2017, 36, 111-125.	0.5	18
130	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Current Heart Failure Reports, 2017, 14, 106-116.	3.3	16
131	Soluble ST2 in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	64
132	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
133	Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic Journal of Cardiology, 2017, 58, 350-359.	1.0	21
134	Prognostic stratification in pulmonary hypertension: A multi-biomarker approach. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 111-125.	0.2	16
135	Effects of obesity on IL-33/ST2 system in heart, adipose tissue and liver: study in the experimental model of Zucker rats. Experimental and Molecular Pathology, 2017, 102, 354-359.	2.1	13
136	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clinical Chemistry, 2017, 63, 211-222.	3.2	41
137	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2378-2388.	2.8	108
138	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	2.2	4
139	Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke. Annals of Clinical and Translational Neurology, 2017, 4, 553-563.	3.7	32
140	Role of cardiac inflammation in right ventricular failure. Cardiovascular Research, 2017, 113, 1441-1452.	3.8	58
141	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2017, 14, 434-443.	3.3	15
142	Clinical Applications of Biomarkers in Atrial Fibrillation. American Journal of Medicine, 2017, 130, 1351-1357.	1.5	39
143	Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2. Journal of the American Heart Association, 2017, 6, .	3.7	18
144	The integrated value of sST2 and global longitudinal strain in the early stratification of patients with severe aortic valve stenosis: a translational imaging approach. International Journal of Cardiovascular Imaging, 2017, 33, 1915-1920.	1.5	14
145	Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 986-993.	1.6	23

#	ARTICLE	IF	CITATIONS
146	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	4.1	127
147	Editorial commentary: Biomarkers in heart failure, between scientific scrutiny and exploration. Trends in Cardiovascular Medicine, 2017, 27, 134-135.	4.9	0
148	Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study. Blood Purification, 2017, 43, 37-45.	1.8	16
149	Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. Annals of Laboratory Medicine, 2017, 37, 137-146.	2.5	20
150	Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates. PLoS ONE, 2017, 12, e0181123.	2.5	7
151	Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatolian Journal of Cardiology, 2017, 18, 200-205.	0.9	7
152	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. International Journal of Cardiology, 2018, 257, 188-192.	1.7	32
153	An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?. Current Heart Failure Reports, 2018, 15, 24-36.	3.3	13
154	Monitoring Biomarkers in Patients Receiving Neprilysin Inhibitors. Current Emergency and Hospital Medicine Reports, 2018, 6, 8-16.	1.5	4
155	The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart, 2018, 5, e000750.	2.3	24
156	Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz, 2018, 43, 455-460.	1.1	12
157	Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction "A multicenter study. Indian Heart Journal, 2018, 70, S79-S84.	0.5	17
158	A Critical Therapeutic Target to Inhibit Apoptosis in Relevant Heart Failure: An Overview. American Journal of Advanced Drug Delivery, 2018, 06, .	0.2	0
159	OBSOLETE: Biomarkers in Heart Failure, Use of. , 2018, , .		0
160	ST2 and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology, 2018, 72, 2321-2323.	2.8	11
161	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126
162	Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology. Biomarkers in Medicine, 2018, 12, 1207-1217.	1.4	7
163	Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients. International Journal of Medical Sciences, 2018, 15, 730-737.	2.5	14

#	ARTICLE	IF	CITATIONS
164	ST2 elevation in heart failure, predictive of a high early mortality. Indian Heart Journal, 2018, 70, 822-827.	0.5	14
165	Fibrosis Marker Soluble ST2 Predicts Atrial Fibrillation Recurrence after Cryoballoon Catheter Ablation of Nonvalvular Paroxysmal Atrial Fibrillation. Korean Circulation Journal, 2018, 48, 920.	1.9	35
166	IL-33/ST2 Axis in Organ Fibrosis. Frontiers in Immunology, 2018, 9, 2432.	4.8	145
167	Multimarker Approach to Identify Patients With Higher Mortality and Rehospitalization Rate After Surgical Aortic Valve Replacement for Aortic Stenosis. JACC: Cardiovascular Interventions, 2018, 11, 2172-2181.	2.9	26
168	Comparative symptom biochemistry between moderate and advanced heart failure. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 565-575.	1.6	9
169	Biomarkers in Heart Failure, Use of. , 2018, , 293-302.		0
170	Biomarkers in Cardiorenal Syndromes. BioMed Research International, 2018, 2018, 1-8.	1.9	19
171	The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery. Current Heart Failure Reports, 2018, 15, 250-259.	3.3	13
172	Inflammatory Mediators in Heart Failure. , 2018, , 33-50.		0
173	Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI). Biomarkers, 2018, 23, 773-780.	1.9	12
174	Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-proBNP Before Cardiac Surgery. Journal of the American Heart Association, 2018, 7, .	3.7	19
175	Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. European Journal of Clinical Investigation, 2018, 48, e12994.	3.4	18
176	Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome. Frontiers in Physiology, 2018, 9, 758.	2.8	35
177	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Tj ETQq1 1 0,784314 rgBT /Overl 11, e004446.	3.9	58
178	Established and Emerging Roles of Biomarkers in Heart Failure. Circulation Research, 2018, 123, 614-629.	4.5	200
179	Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. PLoS ONE, 2018, 13, e0202406.	2.5	18
180	Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
181	GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2018, 72, 519-528.	1.9	82

#	ARTICLE	IF	CITATIONS
182	For Whom the Bell Tolls. Current Cardiology Reports, 2019, 21, 106.	2.9	5
183	Soluble ST2 links inflammation to outcome after subarachnoid hemorrhage. Annals of Neurology, 2019, 86, 384-394.	5.3	16
184	Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model. Hypertension Research, 2019, 42, 1664-1671.	2.7	11
185	Clinical and Prognostic Significance of sST2 in Heart Failure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
186	Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.7	48
187	Cytokines in heart failure. Advances in Clinical Chemistry, 2019, 93, 63-113.	3.7	25
188	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	3.4	57
189	Periodontitis is associated with elevated serum levels of cardiac biomarkersâ€”Soluble ST2 and Câ€reactive protein. Journal of Clinical Periodontology, 2019, 46, 809-818.	4.9	20
190	Is lowâ€level <scp>HIV</scp>â€1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?. HIV Medicine, 2019, 20, 571-580.	2.2	19
191	Regenerative Medicine and Biomarkers for Dilated Cardiomyopathy. , 2019, , 173-185.		2
193	Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgeryâ€”Are We There Yet?. Journal of Clinical Medicine, 2019, 8, 559.	2.4	14
194	Comparison of Echocardiographic and Electrocardiographic Mapping for Cardiac Resynchronisation Therapy Optimisation. Cardiology Research and Practice, 2019, 2019, 1-9.	1.1	7
195	Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners. Medicine and Science in Sports and Exercise, 2019, 51, 405-410.	0.4	11
196	Transcriptomic Biomarkers in Safety and Risk Assessment of Chemicals. , 2019, , 1125-1134.		4
197	ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal, 2019, 53, 21-27.	1.2	40
198	Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy. Biomolecules, 2019, 9, 654.	4.0	6
199	Association between the level of serum soluble ST2 and invasively measured aortic pulse pressure in patients undergoing coronary angiography. Medicine (United States), 2019, 98, e14215.	1.0	1
200	Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making. Current Heart Failure Reports, 2019, 16, 274-284.	3.3	10

#	ARTICLE	IF	CITATIONS
201	Development of heart failure risk prediction models based on a multi-marker approach using random forest algorithms. Chinese Medical Journal, 2019, 132, 819-826.	2.3	18
202	Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure. Journal of Cardiovascular Medicine, 2019, 20, 81-90.	1.5	10
203	Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction. Journal of Cardiology, 2019, 73, 326-332.	1.9	17
204	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
205	Tropisetron inhibits sepsis by repressing hyper-inflammation and regulating the cardiac action potential in rat models. Biomedicine and Pharmacotherapy, 2019, 110, 380-388.	5.6	18
206	Elevated Sera sST2 Is Associated With Heart Failure in Men ≥50 Years Old With Myocarditis. Journal of the American Heart Association, 2019, 8, e008968.	3.7	62
207	sST2 as a novel biomarker for the prediction of in-hospital mortality after coronary artery bypass grafting. Biomarkers, 2019, 24, 268-276.	1.9	8
208	Diagnostic value of novel biomarkers for heart failure. Herz, 2020, 45, 65-78.	1.1	17
209	Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). Heart Lung and Circulation, 2020, 29, 337-344.	0.4	29
210	Circulatory factors associated with function and prognosis in patients with severe heart failure. Clinical Research in Cardiology, 2020, 109, 655-672.	3.3	19
211	sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiologica, 2020, 75, 739-747.	0.9	12
212	Can Biomarkers Provide Right Ventricular-Specific Prognostication in the Perioperative Setting?. Journal of Cardiac Failure, 2020, 26, 776-780.	1.7	5
213	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0
214	Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. International Journal of Cardiology, 2020, 304, 116-121.	1.7	7
215	Biomarkers in patients with Takotsubo cardiomyopathy compared to patients with acute anterior ST-elevation myocardial infarction. Biomarkers, 2020, 25, 137-143.	1.9	13
216	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	3.3	21
217	Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis. Coronary Artery Disease, 2020, 31, 628-635.	0.7	9
218	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	4.4	8

#	ARTICLE	IF	CITATIONS
219	Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure. <i>Annals of Palliative Medicine</i> , 2020, 9, 1976-1989.	1.2	7
220	The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. <i>Clinica Chimica Acta</i> , 2020, 510, 507-514.	1.1	10
221	Post-operative acute kidney injury is associated with a biomarker of acute brain injury after paediatric cardiac surgery. <i>Cardiology in the Young</i> , 2020, 30, 505-510.	0.8	2
222	Biomarkers in pulmonary arterial hypertension: Moving closer toward precision medicine?. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 287-288.	0.6	5
223	Distinctive patterns of inflammation across the heart failure syndrome. <i>Heart Failure Reviews</i> , 2021, 26, 1333-1344.	3.9	32
224	Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.7	4
225	ST2 silencing aggravates ventricular remodeling and chronic heart failure in rats by mediating the IL-6/ST2 axis. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1201-1212.	2.7	5
226	Serum soluble ST2 is a potential long-term prognostic biomarker for transient ischaemic attack and ischaemic stroke. <i>European Journal of Neurology</i> , 2020, 27, 2202-2208.	3.3	14
227	Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	4
228	Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death. <i>Journal of Clinical Medicine</i> , 2020, 9, 578.	2.4	20
229	Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 157, 1606-1616.	0.8	20
230	Soluble ST2: A complex and diverse role in several diseases. <i>Clinica Chimica Acta</i> , 2020, 507, 75-87.	1.1	83
231	Elevated soluble-St2 concentrations in preeclampsia correlate with echocardiographic parameters of diastolic dysfunction and return to normal values one year after delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 379-385.	1.5	6
232	Soluble ST2 proteins in male cachectic patients with chronic heart failure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 886-893.	2.6	7
233	Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. <i>Diagnostics</i> , 2021, 11, 133.	2.6	8
234	ST2 in patients with severe aortic stenosis and heart failure. <i>Cardiology Journal</i> , 2021, 28, 129-135.	1.2	10
235	Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis. <i>Cardiology</i> , 2021, 146, 433-440.	1.4	4
236	Biomarkers in Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 223-243.	2.1	10

#	ARTICLE	IF	CITATIONS
237	Association Between Angiotensin Receptorâ€“Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	3.9	27
238	A possible role for ST2 as prognostic biomarker for COVID-19. <i>Vascular Pharmacology</i> , 2021, 138, 106857.	2.1	22
239	Impact of Midregional Nâ€“Terminal Proâ€“Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020917.	3.7	6
240	Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study. <i>Scientific Reports</i> , 2021, 11, 15203.	3.3	5
241	A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT). <i>Disease Markers</i> , 2021, 2021, 1-10.	1.3	13
242	Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome. <i>Heart and Vessels</i> , 2022, 37, 173-183.	1.2	6
243	Increased Serum Levels of soluble ST2 as a Predictor of Disease Progression in Systemic Sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 315-322.	1.1	4
244	Risk prediction model of in-hospital mortality in heart failure with preserved ejection fraction and mid-range ejection fraction: a retrospective cohort study. <i>Biomarkers in Medicine</i> , 2021, 15, 1223-1232.	1.4	1
245	Cardiovascular damage phenotypes and all-cause and CVD mortality in older adults. <i>Annals of Epidemiology</i> , 2021, 63, 35-40.	1.9	2
246	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 597472.	2.4	3
247	Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. <i>Journal of Clinical Investigation</i> , 2013, 123, 4208-4218.	8.2	101
248	Novel biomarkers for cardiovascular risk prediction. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 135-150.	0.2	157
249	Membrane Translocation of IL-33 Receptor in Ventilator Induced Lung Injury. <i>PLoS ONE</i> , 2015, 10, e0121391.	2.5	14
252	miR-487b mitigates chronic heart failure through inhibition of the IL-33/ST2 signaling pathway. <i>Oncotarget</i> , 2017, 8, 51688-51702.	1.8	20
253	Novel cardiovascular biomarkers in patients with cardiovascular diseases undergoing intensive physical exercise. <i>Panminerva Medica</i> , 2020, 62, 135-142.	0.8	5
254	A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients. <i>Journal of Cardiovascular Development and Disease</i> , 2017, 4, 0009.	1.6	16
255	Type 4 Cardiorenal Syndrome: Myocardial Dysfunction, Fibrosis, and Heart Failure in Patients with Chronic Kidney Disease. <i>Journal of Clinical & Experimental Cardiology</i> , 2012, 03, .	0.0	4
256	Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure. <i>Kardiologia Polska</i> , 2014, 72, 725-734.	0.6	12

#	ARTICLE	IF	CITATIONS
257	Soluble ST2 as a Potential Biomarker in Pericardial Fluid of Coronary Artery Patients. Brazilian Journal of Cardiovascular Surgery, 2021, 36, 677-684.	0.6	2
258	Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?. Current Cardiology Reports, 2021, 23, 171.	2.9	2
259	Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure. Russian Journal of Cardiology, 2021, 26, 4530.	1.4	2
260	Biomarkers and Optimal Management of Heart Failure in the Aging Population. , 2014, , 135-146.		0
261	Prognostic value of novel biomarkers compared with detailed biochemical evaluation in patients with heart failure. Polish Archives of Internal Medicine, 2015, 125, 434-442.	0.4	4
262	Effectiveness of the Suppression of Tumorigenicity 2 for Prognosis in Heart Failure: Systematic Reviews. The Journal of Health Technology Assessment, 2015, 3, 115-121.	0.2	0
263	Clinical roles of soluble ST2 for the outcomes of cardiac valve operations. Research Ideas and Outcomes, 0, 2, e8849.	1.0	0
264	Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure. Anatolian Journal of Cardiology, 2018, 19, 228.	0.9	0
265	Advances in New Marker ST2 for Heart Failure. Advances in Clinical Medicine, 2019, 09, 451-455.	0.0	0
267	Prognostic Value of ST2 Biomarkers in Hypertonic Disease Patients on the Background of the Chronic Obstructive Pulmonary Disease. Ukraïnskij Zhurnal Medicini Biologicheskogo Ta Sportu, 2019, 4, 146-151.	0.2	1
271	A MULTI-MARKER MODEL FOR PREDICTING DECOMPENSATED HEART FAILURE IN PATIENTS WITH PRIOR ACUTE MYOCARDIAL INFARCTION. EUREKA Health Sciences, 2020, 1, 34-39.	0.1	0
272	Valid cardiac biochemical markers. Part II. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBTJ /Overlock 10 Tf 50	1.4	4
273	Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support. Annals of Cardiothoracic Surgery, 2014, 3, 496-504.	1.7	7
274	Soluble ST2: A Novel Prognostic Biomarker of Heart Failure. Acta Cardiologica Sinica, 2014, 30, 501-3.	0.2	6
275	Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2012, 23, 98-102.	0.7	2
276	ST2 and Galectin-3: Ready for Prime Time?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 238-52.	0.7	18
278	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Frontiers in Cardiovascular Medicine, 2021, 8, 753313.	2.4	19
279	Circulating Blood-Based Biomarkers in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 383.	2.4	6

#	ARTICLE	IF	CITATIONS
280	THE ROLE OF NT-PROBNP AND ST2 BIOMARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME. Wiadomości Lekarskie, 2022, 75, 34-38.	0.3	1
281	Changes in transcriptomic landscape in human end-stage heart failure with distinct etiology. IScience, 2022, 25, 103935.	4.1	4
282	Prognostic utility of soluble ST2 biomarker in heart failure patients with reduced ejection fraction. International Journal of Clinical Biochemistry and Research, 2022, 9, 22-27.	0.1	0
283	Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of Personalized Medicine, 2022, 12, 603.	2.5	5
284	Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis. Journal of the American Heart Association, 2022, 11, e024417.	3.7	16
286	Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals. Scientific Reports, 2022, 12, 6569.	3.3	5
287	Effect of ß2-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction. Bulletin of Siberian Medicine, 2022, 21, 35-46.	0.3	0
288	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 2022, 6, 3707-3715.	5.2	9
290	New aspects in cardiorenal syndrome and HFpEF. CKJ: Clinical Kidney Journal, 2022, 15, 1807-1815.	2.9	7
291	Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: <scp>the EVALUATEâ€œHF trial</scp>. European Journal of Heart Failure, 2022, 24, 1200-1208.	7.1	10
292	Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. CKJ: Clinical Kidney Journal, 2022, 15, 1915-1923.	2.9	3
293	Association of ST2 Elevation in the Early Third Trimester with Heart Failure and Pre-Eclampsia in the Peripartum Period. Journal of Women's Health, 0, , .	3.3	0
294	Soluble ST2: a valuable prognostic marker in heart failure. Heart Failure Reviews, 2022, 27, 2155-2164.	3.9	8
295	Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease. BMC Veterinary Research, 2022, 18, .	1.9	4
296	Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals. Journal of Clinical Medicine, 2022, 11, 4693.	2.4	3
297	Prediction of Left Ventricular Reverse Remodelling: A Mini Review on Clinical Aspects. Cardiology, 2022, 147, 521-528.	1.4	2
298	Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping. Current Heart Failure Reports, 0, , .	3.3	3
299	New Biomarkers and Their Potential Role in Heart Failure Treatment Optimisationâ€œAn African Perspective. Journal of Cardiovascular Development and Disease, 2022, 9, 335.	1.6	6

#	ARTICLE	IF	CITATIONS
300	Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
301	Advances in congestive heart failure biomarkers. <i>Advances in Clinical Chemistry</i> , 2023, , 205-248.	3.7	3
302	Prognostic Value of Combined Biomarkers in Patients With Heart Failure: The Heartmarker Score. <i>Annals of Laboratory Medicine</i> , 2023, 43, 253-262.	2.5	2
303	Biomarkers in Pulmonary Arterial Hypertension. <i>Diagnostics</i> , 2022, 12, 3033.	2.6	3
304	Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature. <i>Biomolecules</i> , 2023, 13, 173.	4.0	3
305	Soluble ST2 as a New Oxidative Stress and Inflammation Marker in Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2579.	2.6	4
306	Biomarker sST2 in Adults with Transposition of the Great Arteries Palliated by Mustard Procedure: A Five-Year Follow-up. <i>Pediatric Cardiology</i> , 2023, 44, 927-932.	1.3	0
307	GDF-15 and solubleÂST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension. <i>Biomarkers in Medicine</i> , 2022, 16, 1193-1207.	1.4	2
308	Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology. <i>Current Cardiology Reports</i> , 2023, 25, 133-146.	2.9	7
309	New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5089.	4.1	8
310	Serum-soluble suppression of tumourigenicity-2 as a biomarker in children with congestive heart failure. <i>Cardiology in the Young</i> , 0, , 1-6.	0.8	0
311	Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. <i>Biomedicines</i> , 2023, 11, 917.	3.2	9
312	Differential Expression of <i>Caveolin-3</i>, Suppression of Tumorigenicity 2</i>, and <i>Growth Differentiation Factor-15</i> Genes and Their Association with Acute Myocardial Infarction: A Cross-Sectional Study in a Multi-Specialty Hospital in Tamil Nadu. <i>Genetic Testing and Molecular Biomarkers</i> , 2023, 27, 109-119.	0.7	0
313	Application and Progress of Biomarkers in Heart Failure. <i>Advances in Clinical Medicine</i> , 2023, 13, 7183-7190.	0.0	0
314	Prognostic Value of sST2 in Heart Failure. <i>Journal of Clinical Medicine</i> , 2023, 12, 3970.	2.4	2
315	Establishment of Reference Intervals for Soluble Suppression of Tumorigenicity 2 in the Elderly South Korean Population. , 2023, 45, 76-80.		0
316	Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 468.	1.6	2
317	Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device. <i>International Journal of Molecular Sciences</i> , 2024, 25, 288.	4.1	0

#	ARTICLE	IF	CITATIONS
318	Associa��o do N�vel de ST2 Sol�vel com Mortalidade em 6 Meses e/ou Hospitaliza��o Recorrente Relacionada a Doen�as Cardiovasculares em Embolia Pulmonar. Arquivos Brasileiros De Cardiologia, 2024, 121, .	0.8	0
319	Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0